ScreenerHero

GANXGT Gain Therapeutics SA

NAS · US · Healthcare · Biotechnology · gaintherapeutics.com
2.005USD-3.14%Mkt Cap: 87.51M $P/E: —

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap87.51M $
Enterprise Value73.94M $
Revenue (TTM)—
Gross Profit-9.99M $
Net Income (TTM)-20.16M $
Revenue/Share—
Last Price2.005 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.64
PEG—
EV/EBITDA-3.84
EV/Revenue—
P/S—
P/B7.59
EPS (TTM)-0.48
EPS (Forward)-0.54
52W Range
1.53017% of range4.340
52W High4.340 USD
52W Low1.530 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-108.60%
ROA-88.35%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.47M $
CapEx (TTM)—
FCF Margin—
FCF Yield-12.73%
Net Debt-12.47M $
Net Debt/EBITDA0.65
Balance Sheet
Debt/Equity0.04
Current Ratio4.36
Quick Ratio4.11
Book Value/Sh0.2610 USD
Cash/Share0.3000 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.200 USD
Upside (mean)+259.1%
Target Range5.000 USD – 8.000 USD
$5.000+259.1% to mean$8.000
# Analysts5
Ownership
Shares Out.43.64M
Float42.64M
Insiders2.23%
Institutions19.87%
Short Interest
Short Ratio4.0d
Short % Float7.71%
Short % Out.7.53%
Shares Short3.21M
Short (prev mo.)3.61M
Technical
SMA 501.827 (+9.8%)
SMA 2002.196 (-8.7%)
Beta0.20
S&P 52W Chg18.16%
Avg Vol (30d)577.09K
Avg Vol (10d)609.22K
Technical Indicators
RSI (14)56.3
MACD0.0782
MACD Signal0.0538
MACD Hist.+0.0244
BB Upper2.203 USD
BB Middle1.877 USD
BB Lower1.552 USD
BB Width34.68%
ATR (14)0.1274 USD
Vol Ratio (20d)0.48x